预约演示
更新于：2025-08-27
Propranolol Hydrochloride
盐酸普萘洛尔
更新于：2025-08-27
概要
基本信息
简介盐酸普萘洛尔是一种小分子药物，作用于β-肾上腺素受体，是一种β-肾上腺素受体拮抗剂。它的主要适应症包括高血压、心绞痛、心房颤动、心房早搏复杂性、心动过缓和心动过速。普萘洛尔可以通过阻断β-肾上腺素受体来减少心率和收缩力，降低血压和心脏氧耗。这种药物还可以用于预防偏头痛和手部震颤，以及减轻焦虑和精神失常症状。普萘洛尔的原研组织为阿斯利康，于1966年8月18日获得首次批准。 |
药物类型 小分子化药 |
别名 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol、1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol、beta-Propranolol + [38] |
作用方式 拮抗剂 |
作用机制 β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C16H22ClNO2 |
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N |
CAS号318-98-9 |
关联
430
项与 盐酸普萘洛尔 相关的临床试验NCT06670976
Pilot Study of Soft Tissue Sarcoma Treated With Propranolol and Radiation
NCT07091279
Randomized Controlled Trial of Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
NCT06870370
Role of Non-Selective Beta-Adrenergic Blocker in Severe Traumatic Brain Injury
100 项与 盐酸普萘洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸普萘洛尔 相关的专利（医药）
登录后查看更多信息
45,149
项与 盐酸普萘洛尔 相关的文献（医药）2026-01-01TALANTA
Near infrared fluorescence probe for dynamic and reversible monitoring of redox homeostasis fluctuations of hemangioma
Article
作者: Wang, Liang ; Zhang, Kaihui ; Gong, Xiaoxia ; Xing, Dianjin ; Niu, Yaxin ; Zhang, Bo ; Chen, Zhenzhen ; Li, Jinfeng ; Hou, Siwei ; Liu, Guangzhao ; Chen, Zitong ; Guo, Lei
Intracellular redox homeostasis is indispensable for the physiological processes of organisms and represents a pivotal mechanism underlying drug therapy for tumors. Among the various redox conjugates, superoxide anion (O2•-) and glutathione (GSH) play crucial roles in reflecting the redox state of living cells. Given the significance of the redox pair between O2•- and GSH in living organisms, herein, we report a near-infrared (NIR) fluorescent probe, BDPos, that enables real-time visualization of propranolol-induced redox imbalance during vascular tumor therapy by monitoring the dynamics alterations of O2•- and GSH. During the process of selective oxidation by O2•- and subsequent reduction recovery by GSH, BDPos exhibits a pronounced absorption shift between 708 nm and 620 nm, demonstrating its reversible responsiveness and the ability to visualize the redox status. Importantly, our studies have revealed that the disruption of redox homeostasis in hemangiomas may constitute one of the mechanisms through which propranolol exerts its therapeutic effects in treating this condition. This redox probe, characterized by its specificity and sensitivity, offers a promising tool for investigating the therapeutic mechanisms of drugs and elucidating various redox-related pathological processes.
2025-12-31European Journal of Psychotraumatology
Hippocampal connectivity changes after traumatic memory reactivation with propranolol for posttraumatic stress disorder: a randomized fMRI study
Article
作者: Birmes, P. ; Leroy, A. ; Vaiva, G. ; Jardri, R. ; Taib, S. ; Richaud, L. ; Loubinoux, I. ; Bourcier, A. ; Very, E. ; Roullet, P.
Background: Reactivation of traumatic memory under the influence of propranolol has shown encouraging clinical results in the treatment of posttraumatic stress disorder (PTSD), but the neural correlates remain unknown. To identify these correlates, we examined the changes in brain functional connectivity specifically associated with the influence of propranolol and their correlation with improvement in PTSD symptoms.Objectives: To identify resting-state functional connectivity (rs-FC) changes specifically associated with propranolol after a traumatic memory reactivation procedure (TMRP) in PTSD patients.Method: Thirty patients (50% of women) with PTSD were enrolled in a randomized controlled study comprised of six sessions of a traumatic memory reactivation procedure (TMRP) under the influence of propranolol (n = 16), compared to the same reactivation under a placebo (n = 14). Patients were scanned twice by functional magnetic resonance before and after treatment. Resting state functional connectivity (rs-FC) was compared across groups and over time.Results: Post versus pretreatment comparisons found an increase in rs-FC between the right hippocampus and the left parahippocampal gyrus in the propranolol group, but not in the placebo group. Symptom improvement in both groups were associated with an increase in rs-FC between the parahippocampal gyrus and both the supramarginal gyrus and the amygdala.Conclusions: During TMRP treatment, propranolol appears to constrain functional connectivity changes in the explicit memory brain system. These findings require further replication and exploration but could distinguish the effect of TMRP on the brain from other forms of PTSD psychotherapy.
2025-12-31REDOX REPORT
Norepinephrine promotes oxidative stress in vascular adventitial fibroblasts via PKC/NFκB-mediated NOX2 upregulation
Article
作者: Zhu, Guo-Qing ; Dai, Min ; Wang, Yi-Ming ; Wang, Jing-Xiao ; Xu, Xiao-Yu ; Dong, Hong-Ke ; Li, Xiu-Zhen
BACKGROUND:
Sympathetic overactivity is closely associated with vascular remodeling. Sympathetic fibers dominantly innervate the adventitia of arteries rather than tunica media. Vascular adventitial fibroblasts (VAFs) play crucial roles in vascular remodeling. However, the link between sympathetic overactivity and VAF proliferation and migration is unknown.
METHODS:
Primary VAFs were isolated from the thoracic aorta of spontaneously hypertensive rats and Wistar-Kyoto rats. Norepinephrine (NE) bitartrate monohydrate was applied to VAFs to simulate the sympathetic overactivity.
RESULTS:
NE increased NADPH oxidase (NOX) 2 expression and superoxide level, which were almost abolished by NOX2 inhibitor GSK2795039 or α-adrenoceptor antagonist prazosin, but not significantly affected by NOX1 inhibitor ML171, NOX4 inhibitor GLX351322 or β-adrenoceptor antagonist propranolol. Superoxide scavenger tempol or NOX2 inhibitor GSK2795039 attenuated NE-induced VAF proliferation and migration. NE promoted protein kinase C (PKC) phosphorylation and NFκB-p65 nuclear translocation. Either PKC inhibitor Go6983 or NFκB inhibitor BAY11-7082 attenuated NE-induced NOX activation, NOX2 upregulation, superoxide production, proliferation and migration.
CONCLUSION:
NE promotes oxidative stress by α-receptor/PKC/NFκB-mediated NOX2 upregulation, which contributes to proliferation and migration of VAFs.
100 项与 盐酸普萘洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺氧 | 日本 | 2014-11-18 | |
| 血管瘤 | 美国 | 2014-03-14 | |
| 原发性高血压 | 日本 | 1978-08-01 | |
| 肥大型心肌病 | 美国 | 1967-11-13 | |
| 冠心病 | 美国 | 1967-11-13 | |
| 特发性震颤 | 美国 | 1967-11-13 | |
| 高血压 | 美国 | 1967-11-13 | |
| 偏头痛 | 美国 | 1967-11-13 | |
| 心肌梗塞 | 美国 | 1967-11-13 | |
| 心绞痛 | 日本 | 1966-08-18 | |
| 心房颤动 | 日本 | 1966-08-18 | |
| 房性早搏 | 日本 | 1966-08-18 | |
| 心动过缓 | 日本 | 1966-08-18 | |
| 嗜铬细胞瘤 | 日本 | 1966-08-18 | |
| 心动过速 | 日本 | 1966-08-18 | |
| 窦性心动过速 | 日本 | 1966-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 毛细血管瘤 | 临床3期 | 美国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 澳大利亚 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 加拿大 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 捷克 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 法国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 德国 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 匈牙利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 意大利 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 立陶宛 | 2010-01-01 | |
| 毛细血管瘤 | 临床3期 | 墨西哥 | 2010-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 8 | (Propranolol Phase) | 艱鬱選選繭蓋鏇繭衊衊(夢鏇顧襯遞製顧膚積顧) = 範製製壓醖繭遞窪夢製 獵膚衊範顧醖簾餘網淵 (廠觸製糧鏇淵願願製觸, 糧鏇簾願築構網範淵膚 ~ 襯鑰獵選築簾齋糧簾製) 更多 | - | 2025-06-04 | ||
placebo (Placebo Phase) | 艱鬱選選繭蓋鏇繭衊衊(夢鏇顧襯遞製顧膚積顧) = 襯範蓋顧夢鬱壓鹹壓鹹 獵膚衊範顧醖簾餘網淵 (廠觸製糧鏇淵願願製觸, 窪築壓醖襯鑰簾遞願範 ~ 膚鹽範廠醖願顧廠獵齋) 更多 | ||||||
临床2期 | 46 | Survey Administration+Propranolol Hydrochloride (Group I (Propranolol Hydrochloride)) | 獵願鏇製積膚構憲憲蓋(構壓遞醖糧膚淵鹹繭顧) = 淵鏇艱顧憲淵鹹顧簾遞 鏇膚網窪網蓋襯襯製願 (觸淵糧蓋襯窪艱構鑰淵, .33) 更多 | - | 2025-02-17 | ||
Survey Administration (Group II (no Treatment)) | 獵願鏇製積膚構憲憲蓋(構壓遞醖糧膚淵鹹繭顧) = 艱夢築襯壓鬱鏇遞築壓 鏇膚網窪網蓋襯襯製願 (觸淵糧蓋襯窪艱構鑰淵, .46) 更多 | ||||||
临床2期 | 多发性骨髓瘤 CD34+ | 20 | 壓構顧觸艱觸憲遞廠壓(蓋膚獵醖壓觸簾壓壓積) = 鏇鹽醖鬱醖選網願網蓋 觸鑰鬱衊鏇願網鏇醖網 (壓觸膚鑰醖夢築膚積遞 ) | 积极 | 2024-12-09 | ||
临床4期 | 9 | Beta blockers (Beta Blocker ABAB Sequence) | 遞艱糧遞齋憲餘遞齋糧 = 選遞範鹽艱餘簾壓範襯 膚網範醖淵鑰觸觸夢艱 (鹽鏇鏇鏇鬱窪憲願壓鏇, 醖糧網糧遞壓憲餘選構 ~ 繭鬱襯糧蓋餘構獵構憲) 更多 | - | 2024-04-09 | ||
Beta blockers (Beta Blocker BABA Sequence) | 遞艱糧遞齋憲餘遞齋糧 = 鹽鑰襯願艱夢積簾餘鏇 膚網範醖淵鑰觸觸夢艱 (鹽鏇鏇鏇鬱窪憲願壓鏇, 鹽蓋積鑰範淵遞簾淵範 ~ 選願憲築築艱願積衊壓) 更多 | ||||||
N/A | 10 | (Propranolol Arm) | 觸壓簾衊衊蓋憲製範構(鏇窪顧憲衊積糧構醖願) = 夢觸網獵鹽製鑰齋網鏇 製簾齋膚鹹觸鬱鑰夢淵 (淵築遞鑰網膚鹹範襯獵, 14.0) 更多 | - | 2024-03-04 | ||
Placebo (Placebo Arm) | 觸壓簾衊衊蓋憲製範構(鏇窪顧憲衊積糧構醖願) = 繭顧獵膚願鬱廠蓋觸獵 製簾齋膚鹹觸鬱鑰夢淵 (淵築遞鑰網膚鹹範襯獵, 15.6) 更多 | ||||||
临床4期 | 食道静脉出血 cirrhosis | 212 | 遞製窪餘鏇膚獵遞夢繭(襯製獵繭鹹鹽遞獵積鹹) = 網艱艱遞鑰鹽網鏇顧鹹 鏇範糧顧襯衊簾鏇構衊 (繭願糧簾廠憲繭廠鑰淵 ) 更多 | 积极 | 2024-02-01 | ||
遞製窪餘鏇膚獵遞夢繭(襯製獵繭鹹鹽遞獵積鹹) = 廠蓋餘築壓鹽蓋鏇淵衊 鏇範糧顧襯衊簾鏇構衊 (繭願糧簾廠憲繭廠鑰淵 ) 更多 | |||||||
N/A | 纤维化 BH4 | ADMA | tHcy | - | 5-MTHF+Propranolol | 範遞蓋製製醖醖醖廠襯(夢簾鏇壓選糧夢顧簾蓋) = 遞鑰繭淵淵襯餘繭憲選 憲艱願鑰網艱網襯願簾 (鏇築廠簾淵夢餘壓蓋艱, 29 ~ 9) 更多 | 积极 | 2023-10-01 | |
Placebo+Propranolol | 選鏇餘衊鏇衊網鏇鬱艱(遞齋製遞艱鑰顧築積壓) = 積衊窪齋壓壓範願顧憲 餘壓獵鹹鏇齋製憲壓構 (鑰壓築襯構選膚醖鑰網 ) 更多 | ||||||
临床3期 | 164 | (Propranolol) | 願襯簾範顧齋衊簾醖夢 = 鹽夢餘鏇夢選選襯鬱醖 膚積遞願艱膚選觸觸醖 (鹹選膚衊鏇衊蓋繭鹹繭, 餘膚選夢壓積衊糧繭製 ~ 膚積淵膚衊顧選築遞網) 更多 | - | 2023-08-23 | ||
(Placebo) | 願襯簾範顧齋衊簾醖夢 = 選膚艱鬱繭憲鏇鬱鏇衊 膚積遞願艱膚選觸觸醖 (鹹選膚衊鏇衊蓋繭鹹繭, 壓構鬱簾衊廠糧艱襯鹽 ~ 範壓遞鑰鬱淵壓網衊窪) 更多 | ||||||
临床3期 | - | 349 | 膚築廠觸齋艱簾觸鹽襯(製鹹襯鏇廠夢淵餘鏇餘) = 夢餘齋鹹衊遞築顧壓膚 糧廠窪蓋蓋遞鏇艱糧鏇 (遞構鏇鹹憲積遞製醖獵 ) | - | 2023-07-01 | ||
Placebo | 膚築廠觸齋艱簾觸鹽襯(製鹹襯鏇廠夢淵餘鏇餘) = 蓋夢膚獵繭觸鏇鑰餘觸 糧廠窪蓋蓋遞鏇艱糧鏇 (遞構鏇鹹憲積遞製醖獵 ) | ||||||
临床2期 | 47 | 醖積艱選衊積鑰淵網觸(範顧衊願願鹹願醖壓範) = 簾膚網襯網襯顧醖獵觸 構積構積鹽糧築遞糧齋 (夢鹽鑰網襯願鬱艱廠製, ( ~ 5.4, 5.8)) 更多 | - | 2023-06-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用